Buscar
Mostrando ítems 1-3 de 3
Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
(Taylor&Francis, 2020-05-06)
[Abstract]
Objective: To estimate the cost-effectiveness of second-line pharmacological treatments in patients
with acromegaly resistant to first-generation somatostatin analogues (FG SSA) from the Spanish
National ...
Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study
(Springer, 2019-02-13)
[Abstract] PURPOSE: The burden of chronic daily subcutaneous administration of pegvisomant on adherence has not been previously studied. This study was aimed to determine the adherence to pegvisomant treatment in acromegaly ...
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: the ACROCOMB study
(Elsevier, 2016-11-04)
[Abstract] PURPOSE: To describe real-world use of lanreotide combination therapy for acromegaly.
PATIENTS AND METHODS: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated ...